RecruitingPhase 3NCT07142954

Epidemiology and Biomarker Study in Alzheimer's Disease

A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)


Sponsor

Eli Lilly and Company

Enrollment

3,400 participants

Start Date

Aug 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.


Eligibility

Min Age: 55 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tracks people with no memory problems to find early biological markers of Alzheimer's disease before any symptoms appear. You may be eligible if... - You believe your memory and thinking are currently unimpaired - You have adequate literacy, vision, and hearing to complete memory and thinking tests You may NOT be eligible if... - You have seen a doctor specifically about memory concerns - You have a history or diagnosis of cognitive impairment or a neurodegenerative disease - You are enrolled in or have previously participated in an Alzheimer's drug trial - You currently take or have taken prescription memory medications (such as donepezil, lecanemab, or memantine) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERP-tau217 Test

A plasma test measuring phosphorylated tau at Position 217 (P-tau217).


Locations(4)

Care Access - Houston

Houston, Texas, United States

The University of Tokyo Hospital

Bunkyō City, Japan

Souseikai Sumida Hospital

Tokyo, Japan

Higashi Shinjuku Clinic

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07142954


Related Trials